- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Geron Corp (GERN)
| Open: | 1.1200 | Day's Range: | 1.1200 - 1.1400 | Volume: | 275,068 |
|---|---|---|---|---|---|
| Previous Close: | 1.1200 | 52wk Range: | 0.9100 - 2.9900 | 1-Yr Rtn: | -19.42% |
Key Statistics for GERN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.4600 |
| Est. EPS (USD) (12/2013) | -0.2900 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 146.24 |
| Shares Outstanding (M) | 130.57 |
| 30 Day Average Volume | 668,088 |
| Price/Book (mrq) | 1.9206 |
| Price/Sale (ttm) | 64.3145 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GERN
Company Profile & Key Executives for GERN
Geron Corporation, a biopharmaceutical company, discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes.
| John A ScarlettPresident/CEO | Stephen N RosenfieldExec VP:Legal Affairs/Secy/Gen Counsel |
| Andrew J Grethlein "Andy"Exec VP:Tech Ops/Acting Head:Research | Olivia K BloomSenior VP:Finance/CFO/Treasurer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GERN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page